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1  | INTRODUCTION
Human papillomavirus (HPV) vaccines have been available since
2006.Numerousclinicaltrialsofquadrivalent(HPVtypes6,11,16,
18) and bivalent (HPV types 16, 18)HPVvaccines demonstrated
nearly 100%prophylactic efficacy againstvaccine typepersistent
infections and cervical intraepithelial neoplasia (CIN), the neces-
saryprecursorstocervicalcancer,1–3leadingtoapprovalandcom-
mercialavailability.Thesevaccineshaveproventobe long-lasting




geted by the vaccine.9 In addition to primary safety assessments
conductedasapartoftheoriginalefficacytrials,10expertagencies
have maintained vigilant post-licensure monitoring of the safety




Since April 2009, the WHO has recommended that HPV vac-
cination be included in national immunization programs, provided
that in each countrypreventing cervical cancer constitutes apublic
healthpriority, introduction isprogrammatically feasible,sustainable
financingcanbesecured,andthecost-effectivenessofHPVvaccina-
tionstrategiesareconsidered.13In2014theWHOStrategicAdvisory
GroupofExpertson immunization reviewednew researchand rec-
ommendedrevisionstotheWHOpositionpapertoreducethepre-
viouslyrequiredthree-dosescheduletoatwo-doseschedule(0and
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are currently eligible to access vaccines at these discounted prices
throughGavi.Countries can apply fornational introductionofHPV
vaccine throughGavi, to receive subsidizedvaccineandaone-time
vaccineintroductiongrantat$2.40pereligiblegirlaspartialsupport
















2  | PROGRESS TO DATE IN LLMICS
InitialnationalintroductionsofHPVvaccineoccurredinhigh-income
countriesandfocusedonadolescentgirlsaged12–14yearsthrough
school-based programs.19,20 Some early adopter countries imple-
mentedtime-limitedcatch-upcampaignsforyoungwomenuptoage
18yearsorolder.National introductionsofHPVvaccineexpanded
in high-resource countries from 2008–2012, with a few countries,
suchasDenmark,opting forclinic-baseddelivery.20Mostcountries
providethevaccinefree-of-chargeorfullyreimbursablethroughtheir




2.1 | Early pilots and national introductions
Atthetimeoftheinitialintroductionsinhigh-incomecountries,there
wasuncertaintyastowhetherandhowHPVvaccinescouldbedeliv-
ered in low-resource settings.21,22 To study these questions, PATH















Two countries—Bhutan and Rwanda—introduced HPV vaccine
nationallywith donations fromMerck&Co. In 2010, Bhutan rolled
outa school-basednationalprogram forall girls aged12years,plus
catch-up vaccinations for the 13–18-year-old female population.36 
Coverage in thefirstyearwas99%among12-year-oldsand89% in
thecatch-uppopulation.Thecountryswitchedtoroutinedeliveryin
health facilities from2011–2013 for several reasons, including con-














cialassistance, scientificadvances,andprogramtools. In late2012,
assistanceforLLMICsincreasedwiththeannouncementbyGaviofa
purchasepriceof$4.50–$4.60perdoseofHPVvaccinefromMerck





from eligibility forGavi support prior to 2013. By and large, coun-
triesaretargetingvaccinationstoayoungerage,frequentlyaged9or
10years,andchoosingtouseprimaryschoolsasalocationforvac-
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population,costdeclinedand feasibilityofdelivery increased.39The













tries andgeneratedmaterials inmultiple languages for countries to






















ofvaccineandhuman resourcesneeds, coordinatingwith schools for
vaccinationdays, engaging health personnel forvaccine delivery, and
supervisingregularlytohelpcorrectdeficienciesduringtheprogram.52 






Because of the high disease burden, the encouraging results
of the three evaluations of this program, and the funding opportu-
nities offered by Gavi, Senegal decided to introduce the vaccine
at the national level. With broad involvement from the Ministry






















can apply the knowledge, experience, and evidence now available.
Access tonumerous tools and resources, theavailabilityof compe-
tenttechnicalassistancefromexperiencedpartners,andfosteringof
country-to-countrylearningcouldbecatalyticoverthecomingyears.













keepingmomentum. Several agencies and initiatives provide timely
informationontheglobalburdenofdiseaseandthedisproportionate
impactcervical cancerhas inLLMICs.53,54TheFirstLadies Initiative
andtheCervicalCancerPreventionInitiativeareexamplesofforums
that are used to build political engagement and commitment from
countrydecisionmakers.55,56
Momentum for action also can be supported by new scientific
evidence.Theevidenceisbecomingmorerobustforthetremendous
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impact thatHPVvaccines are having on infection and disease out-
comes.Todate,morethan40studiesofincident,persistentorprev-
alent infections, genitalwarts, andCINacrossmany countries have
demonstrated significant reductions in vaccinated populations.57–61 
Furtherevidenceofherdprotectioninunvaccinatedpopulationsdue
toprotectionprovidedbyHPVvaccineprograms,57,61eveninplaces
with low coverage,57,59 is particularly encouraging for stakehold-
erswhoworry that high coverage is too difficult to achieve.These
advancesneedtobebroughttotheattentionofdecisionmakersand





of poor groundwork include not coordinating with the education
sector for school-based vaccinations39–41; not allowing sufficient
















$9.21 per dose (three-dose schedule).39 For comparison, the two




The cost per dose in HPV demonstration programs masks two
important dynamics—first, the proportion attributable to startup
expensesversusthatforrecurrentcosts;andsecond,thecomponents
F IGURE  1  (A)AccumulationofglobalHPVvaccineexperience,2007.(B)AccumulationofglobalHPVvaccineexperience,2010. 
(C)AccumulationofglobalHPVvaccineexperience,2013.(D)AccumulationofglobalHPVvaccineexperience,October2016.[Colourfigurecan
beviewedatwileyonlinelibrary.com]
Accumulation of global HPV vaccine experience, 2007(A) (B) Accumulation of global HPV vaccine experience, 2010
(C) Accumulation of global HPV vaccine experience, 2013 (D) Accumulation of global HPV vaccine experience, October 2016
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ordriversofthesecosts(bothstartupandrecurrent).31,66Unpacking
thecost-per-dosedatarevealsthatformostdemonstrationprograms,
approximately50%of the cost per dosewas for expenses incurred




spent on different program componentsvariedwidely across coun-




need to understand the drivers of costs and estimate introduction
startupandrecurrentcostsfordelivery—includingthecostsforvac-
cineprocurement—regardlessofco-financingarrangementsforcoun-
trieseligible forGavi support. Interviews from24LLMICs indicated
concernsaboutfinancialsustainabilitythatwerehinderingdecisions
to scale-up from demonstration programs to national introduction.
Fourfactorswerementioned:vaccineprice;co-financingofvaccines





more likely to gain cost efficiencies for HPV vaccine introduction.
For example, addingHPVvaccination training andmicroplanning to
existing training and planning activities could reduce startup costs.
Deliverycostsforconductingvaccinationsinschoolsmaybereduced
if countries use routine outreaches (largely conducted at schools
already) insteadof stand-aloneoutreaches requiring separate trans-
portandpaymentstohealthworkers.
Tosecurefinances,countriesmayrequiresupporttoreviewtheir
program activities carefully, understand the costs of different com-
ponents(includingvaccinecosts),andmakeprudentchoicestobuild
efficiencies inprogramdesign.National immunizationprogramsthat





Political, programmatic, and financial sustainability follow directly
from overcoming the challenges outlined above. Maintaining
momentumamongpolicymakers,governmentofficials,keystake-
holders, and those who influence them requires concerted and
repeated efforts to foster the enabling environment needed for
political sustainability.Using existinghealth system infrastructure
suchastrainingsessions,outreachprograms,andcommunityedu-
cation programs can boost efficiency. Recent data suggest that
the manufacturing cost of producing quadrivalent HPV vaccine




4  | GOAL FOR 2020:  REACHING 30 
MILLION GIRLS
Aglobal analysis ofHPV vaccination coverage suggested that only
1%ofyoungwomenaged10–20yearsinLLMICshadbeenfullyvac-







In regard to policy changes, the Gavi Board announced signif-
icant changes for HPV vaccines in December 2016.74 The Board
approvedthediscontinuationoftheHPVdemonstrationprogramand








With regard to programmatic advances, vaccinating a multiage
cohort (or “catch-up”)may have advantages comparedwith gradual
vaccinationovertimeofanequalnumberofgirls. Inadditiontothe
potential reduction in delivery costs as vaccination services reach
moregirlsmorequickly,vaccinatinga largerproportionof thepop-
ulation at once can interrupt HPV transmission more significantly,
resulting inpopulation-level benefits and faster appearanceofherd
protection.57,75,76Thewell-documentedlessonslearnedfromLLMICs’
experience preparing for and implementing HPV vaccination pro-




Scientific advances in vaccine development also offer promise.
Anonavalent vaccine, which is similar in constitution to the quad-
rivalentHPVvaccine but protects against five additional oncogenic














ally by 2020 include two being developed by Chinese companies
(InnovaxandWalvax).81–83Technologytransfersofexistingvaccines
tomiddle-incomecountrymanufacturershaveoccurredinBraziland

















vaccineby2020a reality.Weknowwhat it takes.Now,more than
ever,isthetimetomovefromknowledgetoaction.
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Table S1. HPV vaccination experience in low- and lower-middle-
incomecountries,asofDecember2016.
